Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
Summary
The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2 different sites of administration. Primary Objective: * To demonstrate the non-inferiority of the antibody response against all antigens (diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib)) in participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine compared to participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with placebo. Secondary Objectives: * To describe the safety of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine, or administered concomitantly with placebo. * To describe the safety of the CYD dengue vaccine after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim™ vaccine (at Visit 05) or administered alone (at Visit 06). * To describe the safety of the CYD dengue vaccine in all participants after each dose. * To describe the antibody response to each dengue virus serotype (post-Dose 2 and post-Dose 3) after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim vaccine (at Visit 05) or administered alone (at Visit 06). * To describe the antibody response to each dengue virus serotype post-Dose 2 and post-Dose 3.
Timeline
- Start
- 2011-07-18
- Primary completion
- 2014-02-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CYD Dengue Vaccine | Vaccine | 0.5 ml | Subcutaneous |
| Subject | DTaP IPV//Hib vaccine | Vaccine | 0.5 ml | Intramuscular |
| Background | Measles, mumps, and rubella vaccine | Vaccine | 0.5 ml | Subcutaneous |
| Background | Prevnar 13 | Vaccine | 0.5 ml | Intramuscular |